Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease VirusProstate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate CancerMacrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
/in Checkpoint-Inhibitors, Glioblastoma, International Publications, Newcastle Disease VirusImmunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial CarcinomaImmunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsProspect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International PublicationsTargeting the PD-1 pathway in pediatric solid tumors and brain tumors
/in Brain Tumors in Children, Checkpoint-Inhibitors, Glioblastoma, International PublicationsAssessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
/in Checkpoint-Inhibitors, Glioblastoma, International PublicationsTargeting immune checkpoints in malignant glioma
/in Checkpoint-Inhibitors, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de